Approximately 70 women with a history of moderate-to-severe dysmenorrhea participated in this first documented attempt to show prevention of uterine cramping and pain. This double-blind, placebo-controlled clinical trial
Winston will continue as the surviving entity in the merger and as a wholly-owned subsidiary of Getting Ready (GTRY). In connection with the consummation of the merger, GTRY
The multiple ascending dose study is the fourth and final study in the company’s Phase I program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor
Previously Dr Mason was senior vice president of business development at Cambridge Antibody Technology. Dr Mason holds a BSc degree in immunology from University College London and an
The new findings show that Apoptone treatment significantly reduced tumor volume (p < 0.05), and delayed tumor-doubling time relative to that in vehicle-treated animals. An analysis of tumor
Mr Partridge was appointed COO of Visa and interim president of Visa USA in July 2007. He joined Visa USA in October 1999 and has served as president
Mr Brewer replaces Emilio Cordova who has resigned from BASi to pursue other opportunities. Most recently Mr Brewer consulted with companies to develop and implement new business strategies.
Under the contract, PharmAthene will receive initial funding of approximately $13.2 million during a ‘base period’ of performance. During this time the company will be responsible for preclinical
The trial showed that microplasmin was generally well tolerated and also provided some preliminary efficacy data. The MITI IV trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled,
In this double-masked Phase II trial, patients were initially treated with either fixed monthly or quarterly dosing for 12 weeks and then continued to receive treatment for another
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.